[go: up one dir, main page]

PL2544719T3 - Cząsteczki wiążące cd37 i ich immunokoniugaty - Google Patents

Cząsteczki wiążące cd37 i ich immunokoniugaty

Info

Publication number
PL2544719T3
PL2544719T3 PL11754195T PL11754195T PL2544719T3 PL 2544719 T3 PL2544719 T3 PL 2544719T3 PL 11754195 T PL11754195 T PL 11754195T PL 11754195 T PL11754195 T PL 11754195T PL 2544719 T3 PL2544719 T3 PL 2544719T3
Authority
PL
Poland
Prior art keywords
immunoconjugates
binding molecules
molecules
binding
Prior art date
Application number
PL11754195T
Other languages
English (en)
Inventor
Jutta Deckert
Peter Park
Daniel Tavares
Lingyun Rui
Original Assignee
Debiopharm International S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm International S.A. filed Critical Debiopharm International S.A.
Publication of PL2544719T3 publication Critical patent/PL2544719T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PL11754195T 2010-03-12 2011-03-11 Cząsteczki wiążące cd37 i ich immunokoniugaty PL2544719T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31362810P 2010-03-12 2010-03-12
US32731410P 2010-04-23 2010-04-23
US41264410P 2010-11-11 2010-11-11
PCT/US2011/028172 WO2011112978A1 (en) 2010-03-12 2011-03-11 Cd37-binding molecules and immunoconjugates thereof
EP11754195.3A EP2544719B1 (en) 2010-03-12 2011-03-11 Cd37-binding molecules and immunoconjugates thereof

Publications (1)

Publication Number Publication Date
PL2544719T3 true PL2544719T3 (pl) 2020-01-31

Family

ID=44563875

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11754195T PL2544719T3 (pl) 2010-03-12 2011-03-11 Cząsteczki wiążące cd37 i ich immunokoniugaty

Country Status (28)

Country Link
US (5) US8765917B2 (pl)
EP (2) EP3620467A1 (pl)
JP (5) JP5932672B2 (pl)
KR (2) KR101644674B1 (pl)
CN (2) CN106046159B (pl)
AR (1) AR080513A1 (pl)
AU (3) AU2011226672B2 (pl)
BR (1) BR112012023010A8 (pl)
CA (2) CA2792618C (pl)
CY (1) CY1122091T1 (pl)
DK (1) DK2544719T3 (pl)
ES (1) ES2748347T3 (pl)
HR (1) HRP20191688T1 (pl)
HU (1) HUE046360T2 (pl)
IL (2) IL221682A (pl)
LT (1) LT2544719T (pl)
MX (2) MX375439B (pl)
MY (2) MY173839A (pl)
NZ (2) NZ602176A (pl)
PL (1) PL2544719T3 (pl)
PT (1) PT2544719T (pl)
RS (1) RS59389B1 (pl)
RU (2) RU2742743C2 (pl)
SG (3) SG183542A1 (pl)
SI (1) SI2544719T1 (pl)
SM (1) SMT201900549T1 (pl)
TW (2) TWI638662B (pl)
WO (1) WO2011112978A1 (pl)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
NZ602176A (en) 2010-03-12 2015-01-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
ES2562487T3 (es) 2011-02-01 2016-03-04 Huawei Technologies Co., Ltd. Método de economía de energía, dispositivo de punto de acceso y dispositivo de estación
CA2831467C (en) 2011-03-29 2020-03-24 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
EA201391342A1 (ru) * 2011-04-01 2014-11-28 Иммьюноджен, Инк. Cd37-связывающие молекулы и их иммуноконъюгаты
CN109276713A (zh) * 2011-12-13 2019-01-29 诺帝克纳诺维科特股份公司 嵌合的治疗性抗-cd37抗体hh1
MY178120A (en) 2012-02-24 2020-10-05 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
JP2015514716A (ja) * 2012-03-30 2015-05-21 イミュノジェン， インコーポレイテッド Ｃｄ３７に基づく治療の有効性を増大させる方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
RU2018122734A (ru) 2012-10-04 2018-07-24 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент-цитотоксический агент
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US20160319034A1 (en) * 2013-03-14 2016-11-03 Oncomed Pharmaceuticals, Inc. Met-binding agents and uses thereof
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
MX2016001233A (es) 2013-08-01 2016-10-28 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas cd37.
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
CN105934257B (zh) * 2013-12-06 2020-10-09 韩捷 用于含氮和羟基的药物的生物可逆引入基团
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
WO2015175533A2 (en) * 2014-05-13 2015-11-19 Immunogen, Inc. Anti-cd37 immunoconjugate dosing regimens
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
TWI670078B (zh) 2014-05-27 2019-09-01 中央研究院 抗ｃｄ２０醣抗體及其用途
WO2015184002A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
CN106661562A (zh) 2014-05-27 2017-05-10 中央研究院 得自类杆菌属的岩藻糖苷酶及其用途
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
CN109147874A (zh) 2014-09-02 2019-01-04 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
PE20170775A1 (es) 2014-09-03 2017-07-04 Immunogen Inc Derivados de benzodiazepina citotoxicos
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
AU2015327824B2 (en) 2014-10-02 2021-01-07 City Of Hope Multivalent meditopes, meditope-binding antibodies and uses thereof
AU2015349985A1 (en) 2014-11-19 2017-05-25 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2986437A1 (en) 2015-06-08 2016-12-15 Debiopharm International, S.A. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
MA42250B1 (fr) 2015-06-29 2020-11-30 Immunogen Inc Conjugués d'anticorps à cystéine modifiée
CN108699144B (zh) * 2015-08-28 2022-07-19 德彪发姆国际有限公司 用于检测cd37的抗体和测定
JP2019501139A (ja) 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド 医薬製剤及びその使用
WO2017107817A1 (zh) * 2015-12-21 2017-06-29 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
WO2017136623A1 (en) 2016-02-05 2017-08-10 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
CN110392685B (zh) 2016-11-23 2023-07-04 伊缪诺金公司 苯并二氮卓衍生物的选择性磺化
CN116785451A (zh) 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
JP7254710B2 (ja) * 2017-03-16 2023-04-10 ザ ジェネラル ホスピタル コーポレイション Ｃｄ３７を標的にするキメラ抗原受容体
CN110914301B (zh) 2017-03-31 2024-09-06 健玛保控股有限公司 双特异性抗cd37抗体，单克隆抗cd37抗体及其使用方法
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11793885B2 (en) 2017-12-28 2023-10-24 Immunogen, Inc. Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders
MA51666A (fr) 2018-01-24 2020-12-02 Genmab Bv Variants polypeptidiques et leurs utilisations
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
MX2020012755A (es) 2018-05-30 2021-02-26 Debiopharm Int Sa Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
EP3810649A1 (en) 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
AU2019354105A1 (en) 2018-10-04 2021-04-29 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-CD37 antibodies
PL3958977T3 (pl) 2019-04-26 2024-03-11 Immunogen, Inc. Pochodne kamptotecyny
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
EP4055046A1 (en) 2019-11-06 2022-09-14 Genmab B.V. Antibody variant combinations and uses thereof
JP2023514692A (ja) 2020-02-21 2023-04-07 ジェンマブ ビー．ブイ． 糖蛋白質の定量のための方法
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
EP4420683A1 (en) 2021-10-18 2024-08-28 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
AU2023253796A1 (en) 2022-04-14 2024-10-17 Debiopharm Research & Manufacturing S.A. Ligand-drug-conjugates with improved pharmacokinetic and drug release properties
WO2024219442A1 (ja) * 2023-04-19 2024-10-24 第一三共株式会社 抗体－薬物コンジュゲートと他の薬剤との組み合わせ

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5977316A (en) 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US20030054360A1 (en) 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
DE60044997D1 (de) 1999-07-02 2010-11-04 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
MXPA03000306A (es) * 2000-07-12 2004-04-05 Idec Pharma Corp Tratamiento de malignidades de celulas b que usan una combinacion de anticuerpos supresores de celulas b y aplicaciones relacionadas con anticuerpos moduladores inmunes.
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
CA2425208C (en) 2000-09-26 2013-04-09 Duke University Rna aptamers and methods for identifying the same
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2436180C (en) * 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
PL373835A1 (pl) 2001-01-31 2005-09-19 Biogen Idec Inc. Zastosowanie antagonistów CD23 do leczenia choróbnowotworowych
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
DE60233509D1 (de) * 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
JP2005524386A (ja) 2001-11-08 2005-08-18 ▲養▼生堂有限公司 抗ｅ型肝炎ウイルスモノクローナル抗体、又は結合性を有するそのフラグメント、及びそれらの使用
IL161988A0 (en) * 2001-11-16 2005-11-20 Corporation Idec Pharmaceutica Polycistronic expression of antibodies
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004045642A1 (en) * 2002-11-15 2004-06-03 Immunomedics, Inc. Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
US20050124565A1 (en) 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
JP4959136B2 (ja) 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド 細胞内で開裂可能な結合を有する免疫接合体
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
CN1802388B (zh) 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005024042A2 (en) 2003-09-04 2005-03-17 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
FR2867784B1 (fr) 2004-03-17 2006-06-09 Commissariat Energie Atomique Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications
US20050239134A1 (en) 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
US7241598B2 (en) 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
EP1784425A4 (en) 2004-06-30 2009-02-18 Centocor Inc ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
WO2006074397A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
CA2597265C (en) 2005-02-10 2015-03-24 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
DE602006012839D1 (de) 2005-05-20 2010-04-22 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
WO2006133450A2 (en) 2005-06-08 2006-12-14 Duke University Anti-cd19 antibody therapy for the transplantation
RU2423381C2 (ru) * 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP1806365A1 (en) * 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
BRPI0711249A2 (pt) 2006-05-30 2012-03-13 Genentech, Inc. Anticorpos, polinucleotídeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar câncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fabricação
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
JP2009545319A (ja) 2006-08-03 2009-12-24 バクシネックス，インコーポレーテッド 抗ｉｌ−６モノクローナル抗体およびその使用
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
JP2010507394A (ja) 2006-10-24 2010-03-11 トルービオン ファーマスーティカルズ インコーポレイテッド 改良免疫糖タンパク質のための物質および方法
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
RS53008B2 (sr) * 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
BRPI0814060A2 (pt) 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
GB2454915B (en) 2007-11-23 2012-02-15 Schlumberger Holdings Spooling apparatus for well intervention system
WO2009085573A2 (en) 2007-12-28 2009-07-09 Spring Bioscience Corporation Quality control cell device for immunohistochemistry assay and methods of use thereof
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
EP2132228B1 (en) * 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US7740844B2 (en) 2008-04-29 2010-06-22 Taiwan Liposome Co. Ltd Anti-VEGF monoclonal antibody
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
WO2009134976A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc Potent conjugates and hydrophilic linkers
US8563700B2 (en) 2008-06-16 2013-10-22 Immunogen, Inc. Synergistic effects
RU2523419C2 (ru) 2008-07-15 2014-07-20 Дженетек, Инк. Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений
WO2010057047A1 (en) 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
US9090679B2 (en) * 2009-04-17 2015-07-28 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
EP2486023A4 (en) 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
EA201492253A1 (ru) 2009-12-29 2015-06-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Конструкторы, связывающиеся с ron, и способы их использования
WO2011100398A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
NZ602176A (en) 2010-03-12 2015-01-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
EP2558501B1 (en) 2010-04-15 2016-09-07 Alper Biotech, Llc Monoclonal antibodies against her2 antigens, and uses therefor
CA2831467C (en) 2011-03-29 2020-03-24 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
EA201391342A1 (ru) 2011-04-01 2014-11-28 Иммьюноджен, Инк. Cd37-связывающие молекулы и их иммуноконъюгаты
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
CN109276713A (zh) 2011-12-13 2019-01-29 诺帝克纳诺维科特股份公司 嵌合的治疗性抗-cd37抗体hh1
JP2015514716A (ja) 2012-03-30 2015-05-21 イミュノジェン， インコーポレイテッド Ｃｄ３７に基づく治療の有効性を増大させる方法
US20130309224A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with rituximab
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
EP3004395A4 (en) 2013-06-05 2017-01-04 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
EP3332813B1 (en) 2013-06-07 2019-05-29 Nordic Nanovector ASA Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody
IL312865B1 (en) 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
CA2926893C (en) 2013-11-07 2022-04-12 F. Hoffmann-La Roche Ag Combination therapy of an anti cd20 antibody with a btk inhibitor
WO2015116729A2 (en) 2014-01-28 2015-08-06 Emergent Product Development Seattle, Llc Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders
WO2015175533A2 (en) 2014-05-13 2015-11-19 Immunogen, Inc. Anti-cd37 immunoconjugate dosing regimens
CA2986437A1 (en) 2015-06-08 2016-12-15 Debiopharm International, S.A. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
CN108699144B (zh) 2015-08-28 2022-07-19 德彪发姆国际有限公司 用于检测cd37的抗体和测定
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
MX2020012755A (es) 2018-05-30 2021-02-26 Debiopharm Int Sa Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).

Also Published As

Publication number Publication date
EP2544719A1 (en) 2013-01-16
CN102971012A (zh) 2013-03-13
AU2011226672B2 (en) 2015-07-23
JP2015091267A (ja) 2015-05-14
US20160326258A1 (en) 2016-11-10
BR112012023010A2 (pt) 2017-02-07
KR101644674B1 (ko) 2016-08-02
CA2792618A1 (en) 2011-09-15
RU2610662C9 (ru) 2017-07-24
IL252398B (en) 2018-10-31
PT2544719T (pt) 2019-10-17
CA2792618C (en) 2018-09-25
AU2011226672A1 (en) 2012-09-27
EP2544719A4 (en) 2013-10-09
JP2020141693A (ja) 2020-09-10
MY177062A (en) 2020-09-03
EP3620467A1 (en) 2020-03-11
CA3015111C (en) 2022-05-17
US20130295104A1 (en) 2013-11-07
AU2015246118B2 (en) 2017-07-20
RU2017102767A3 (pl) 2020-06-08
ES2748347T3 (es) 2020-03-16
KR20130016272A (ko) 2013-02-14
IL252398A0 (en) 2017-07-31
KR101764572B1 (ko) 2017-08-03
US10202460B2 (en) 2019-02-12
US11466095B2 (en) 2022-10-11
HUE046360T2 (hu) 2020-03-30
US20230287137A1 (en) 2023-09-14
RU2742743C2 (ru) 2021-02-10
RU2610662C2 (ru) 2017-02-14
MX338932B (es) 2016-05-06
JP2016127867A (ja) 2016-07-14
JP5932672B2 (ja) 2016-06-08
IL221682A (en) 2017-06-29
CY1122091T1 (el) 2020-11-25
JP6133340B2 (ja) 2017-05-24
WO2011112978A1 (en) 2011-09-15
MX375439B (es) 2025-03-04
EP2544719B1 (en) 2019-07-03
HRP20191688T1 (hr) 2019-12-27
MX2012010514A (es) 2013-03-20
BR112012023010A8 (pt) 2017-12-26
AR080513A1 (es) 2012-04-11
SG10202001677QA (en) 2020-04-29
TW201607558A (zh) 2016-03-01
JP2018138053A (ja) 2018-09-06
JP2013524777A (ja) 2013-06-20
TWI638662B (zh) 2018-10-21
AU2015246118A1 (en) 2015-11-12
US9346887B2 (en) 2016-05-24
NZ703481A (en) 2016-02-26
MY173839A (en) 2020-02-24
SI2544719T1 (sl) 2019-11-29
TWI593424B (zh) 2017-08-01
US20190218303A1 (en) 2019-07-18
RU2012139045A (ru) 2014-04-20
US8765917B2 (en) 2014-07-01
SMT201900549T1 (it) 2019-11-13
RU2017102767A (ru) 2019-01-18
US20110256153A1 (en) 2011-10-20
NZ602176A (en) 2015-01-30
CN106046159B (zh) 2020-06-16
CN102971012B (zh) 2016-05-04
CN106046159A (zh) 2016-10-26
DK2544719T3 (da) 2019-10-14
LT2544719T (lt) 2019-10-25
RS59389B1 (sr) 2019-11-29
KR20150021112A (ko) 2015-02-27
SG183542A1 (en) 2012-10-30
SG10201501803YA (en) 2015-05-28
AU2017248441A1 (en) 2017-11-02
TW201206481A (en) 2012-02-16
CA3015111A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
IL252398A0 (en) cd37-binding molecules and their immunoconjugates
ZA201307302B (en) Cd37-binding molecules and immunoconjugates thereof
IL250764A0 (en) Antibodies against mesothelin and immune conjugates
IL249669B (en) Converted 5-fluoro-h1-pyrazolopyridines and their use
EP2632490A4 (en) NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
EP2632947A4 (en) NON-ANTAGONIST MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
HK1174543A1 (en) Pyrrolobenzodiazepines and conjugates thereof
GB201010557D0 (en) RNA molecules and uses thereof
ZA201303028B (en) Spacer and components therefor
ZA201208173B (en) Peptices and their use
LT2361936T (lt) Antigeną rišanti molekulė ir jos panaudojimas
SI2552440T1 (sl) Nove kombinacije in uporaba
EP2615094A4 (en) SESTERTERPEN COMPOUNDS AND THEIR USE